VAIL, CO USA (UroToday.com) - Background: Oral medications have become more widely available for treatment of various cancers, and adherence to dosing/ refill patterns, or medication possession, are important considerations for treatment.
Abiraterone acetate (AA), prodrug of aberaterone, which is a novel oral androgen biosynthesis inhibitor approved for metastatic castration resistant prostate cancer. This study reports adherence to AA dosing and administration recommendations by prostate cancer (PC) patients as observed in two separate data sources.
Methods: PC patients with ≥1 AA prescription fill were identified in two retrospective pharmacy claim data sources: 1) Truven Commercial Claims and Encounters; and 2) Symphony ProMetis. Patients with no evidence of recent chemotherapy (NRC) or with evidence of recent chemotherapy (RC) were identified in the 6 months prior to AA initiation. The average AA daily dose per prescription per patient was reported. To evaluate adherence, the Medication Possession Ratio (MPR), a measure of consistency calculated as the sum of the AA days of supply divided by the total number of days between first and end of last AA fill, was assessed for patients with ≥2 AA fills. Data were summarized by descriptive statistics.
Results: In both datasets the mean medication consistency/MPR was greater than 90% and the mean daily dose was within 1% of the recommended daily dose (1 000 mg). Medication consistency and AA daily dose per patient appeared similar between patients with recent chemotherapy and patients without recent chemotherapy.
Conclusions: Results from two observational studies representing >3 700 PC patients reported high levels of AA adherence to AA dosing and administration consistent with prescribing information. Such data support providers’ understanding of the consistency to which AA treated PC patients adhere to AA medication use.
Presented by Chris Kozma, Terra S. Slaton, Lorie A. Ellis, R. Scott McKenzie, Marie-Helene Lafeuille, Amanda M. Grittner, and Patrick Lefebvre at the 24th International Prostate Cancer Update - February 19 - 22, 2014 - Cascade Conference Center - Vail, Colorado USA
CK Consulting, St. Helena Island, SC;
Janssen Scientific Affairs, LLC, Horsham, PA;
Groupe d’analyse, Ltee, Montreal, QC, Canada